Esperion Therapeutics (ESPR) Stock Forecast, Price Target & Predictions
ESPR Stock Forecast
Esperion Therapeutics stock forecast is as follows: an average price target of $16.00 (represents a 798.88% upside from ESPR’s last price of $1.78) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
ESPR Price Target
The average price target for Esperion Therapeutics (ESPR) is $16.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $20.00 to $12.00. This represents a potential 798.88% upside from ESPR's last price of $1.78.
ESPR Analyst Ratings
According to 8 Wall Street analysts, Esperion Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ESPR stock is 0 'Strong Buy' (0.00%), 6 'Buy' (75.00%), 2 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Esperion Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 04, 2022 | Serge Belanger | Needham | $12.00 | $6.53 | 83.77% | 574.16% |
| May 04, 2021 | Derek Archila | Wells Fargo | $20.00 | $25.59 | -21.84% | 1023.60% |
The latest Esperion Therapeutics stock forecast, released on May 04, 2022 by Serge Belanger from Needham, set a price target of $12.00, which represents a 83.77% increase from the stock price at the time of the forecast ($6.53), and a 574.16% increase from ESPR last price ($1.78).
Esperion Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.78 | $1.78 | $1.78 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Esperion Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Esperion Therapeutics's last price of $1.78. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 01, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 20, 2024 | Bank of America Securities | Buy | Underperform | Downgrade |
| May 22, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 15, 2023 | Barclays | - | Overweight | Initialise |
| Jun 15, 2023 | Guggenheim | - | Buy | Initialise |
| Jun 15, 2023 | Cowen & Co. | - | Buy | Upgrade |
| Jun 15, 2023 | Bank of America Securities | - | Buy | Upgrade |
| Mar 16, 2023 | Needham | Buy | Buy | Hold |
| Mar 07, 2023 | Credit Suisse | - | Neutral | Upgrade |
| Feb 03, 2023 | Oppenheimer | - | Outperform | Initialise |
Esperion Therapeutics's last stock rating was published by H.C. Wainwright on Jul 01, 2024. The company gave ESPR a "Buy" rating, the same as its previous rate.
Esperion Therapeutics Financial Forecast
Esperion Therapeutics Revenue Forecast
| Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $33.97M | $25.79M | $24.33M | $18.82M | $18.98M | - | $18.84M | $15.40M | $14.41M | $40.66M | $7.98M | $9.64M | $3.83M | $212.24M | $1.84M | $982.00K | $981.00K | $982.00K | $145.42M |
| Avg Forecast | $94.10M | $88.00M | $191.80M | $101.60M | $81.80M | $73.10M | $61.58M | $52.89M | $47.49M | $83.93M | $28.65M | $29.59M | $24.64M | $21.98M | $20.61M | $19.68M | $18.62M | $15.41M | $14.48M | $11.89M | $42.18M | $19.93M | $12.52M | $4.01M | $147.97M | $471.36K | $891.80K | $900.00K | $24.33M | $69.35M |
| High Forecast | $115.81M | $108.31M | $236.06M | $125.04M | $100.68M | $89.97M | $75.79M | $62.85M | $58.45M | $103.30M | $32.62M | $36.41M | $30.33M | $27.05M | $25.36M | $24.22M | $18.62M | $17.61M | $16.55M | $13.60M | $48.22M | $22.79M | $14.31M | $4.58M | $169.13M | $538.79K | $1.02M | $1.03M | $27.82M | $79.27M |
| Low Forecast | $76.31M | $71.36M | $155.53M | $82.39M | $66.33M | $59.28M | $49.93M | $46.61M | $38.51M | $68.06M | $22.09M | $23.99M | $19.98M | $17.82M | $16.71M | $15.96M | $18.62M | $14.06M | $13.22M | $10.86M | $38.50M | $18.20M | $11.43M | $3.66M | $135.07M | $430.26K | $814.04K | $821.52K | $22.21M | $63.30M |
| # Analysts | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.15% | 1.05% | 1.11% | 0.91% | 0.96% | - | 1.22% | 1.06% | 1.21% | 0.96% | 0.40% | 0.77% | 0.96% | 1.43% | 3.90% | 1.10% | 1.09% | 0.04% | 2.10% |
Esperion Therapeutics's average Quarter revenue forecast for Dec 23 based on 6 analysts is $28.65M, with a low forecast of $22.09M, and a high forecast of $32.62M. ESPR's average Quarter revenue forecast represents a -15.67% decrease compared to the company's last Quarter revenue of $33.97M (Sep 23).
Esperion Therapeutics EBITDA Forecast
| Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-27.53M | $-37.06M | $-47.33M | $-41.16M | $-40.86M | - | $-42.52M | $-51.54M | $-55.58M | $-32.37M | $-82.66M | $-95.39M | $-80.35M | $129.37M | $-73.97M | $-57.72M | $-64.29M | $-54.17M | $87.45M |
| Avg Forecast | $-77.75M | $-72.71M | $-158.48M | $-83.95M | $-67.59M | $-60.40M | $-50.88M | $-43.70M | $-39.24M | $-56.89M | $-23.67M | $-24.45M | $-20.36M | $-51.71M | $-17.03M | $-66.27M | $-15.38M | $-47.01M | $-62.89M | $-60.24M | $-35.04M | $-50.51M | $-92.09M | $-88.99M | $74.90M | $-84.09M | $-66.58M | $-45.50M | $-49.80M | $-57.30M |
| High Forecast | $-63.05M | $-58.96M | $-128.51M | $-68.08M | $-54.81M | $-48.98M | $-41.26M | $-38.51M | $-31.82M | $-45.51M | $-18.26M | $-19.82M | $-16.51M | $-41.37M | $-13.81M | $-53.01M | $-15.38M | $-37.61M | $-50.31M | $-48.19M | $-28.03M | $-40.41M | $-73.67M | $-71.19M | $89.88M | $-67.27M | $-53.27M | $-36.40M | $-39.84M | $-52.31M |
| Low Forecast | $-95.70M | $-89.49M | $-195.05M | $-103.32M | $-83.19M | $-74.34M | $-62.62M | $-51.93M | $-48.30M | $-68.26M | $-26.95M | $-30.09M | $-25.06M | $-62.06M | $-20.96M | $-79.52M | $-15.38M | $-56.42M | $-75.47M | $-72.29M | $-42.05M | $-60.62M | $-110.50M | $-106.79M | $59.92M | $-100.91M | $-79.90M | $-54.60M | $-59.76M | $-65.50M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.13% | 1.82% | 0.92% | 2.42% | 0.62% | - | 0.90% | 0.82% | 0.92% | 0.92% | 1.64% | 1.04% | 0.90% | 1.73% | 0.88% | 0.87% | 1.41% | 1.09% | -1.53% |
4 analysts predict ESPR's average Quarter EBITDA for Sep 20 to be $-88.99M, with a high of $-71.19M and a low of $-106.79M. This is -168.79% lower than Esperion Therapeutics's previous annual EBITDA (Jun 20) of $129.37M.
Esperion Therapeutics Net Income Forecast
| Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $-41.25M | $-49.94M | $-89.22M | $-68.46M | $-68.61M | - | $-70.47M | $-78.55M | $-69.39M | $-43.67M | $-90.94M | $-104.48M | $-85.44M | $124.61M | $-78.25M | $-61.95M | $-68.38M | $-54.22M | $87.38M |
| Avg Forecast | $-18.88M | $-20.77M | $60.41M | $-15.10M | $-28.32M | $-30.21M | $-27.69M | $-32.63M | $-32.50M | $-75.90M | $-90.94M | $-80.82M | $-115.43M | $-69.00M | $-160.18M | $-82.73M | $-176.16M | $-62.73M | $-79.46M | $-75.21M | $-47.27M | $-55.57M | $-100.86M | $-94.63M | $72.14M | $-88.95M | $-71.46M | $-48.39M | $-49.85M | $168.97M |
| High Forecast | $-14.24M | $-15.66M | $78.54M | $-11.39M | $-21.36M | $-22.78M | $-20.88M | $-13.99M | $-24.51M | $-60.72M | $-68.63M | $-60.95M | $-87.06M | $-55.20M | $-120.81M | $-66.18M | $-176.16M | $-50.19M | $-63.57M | $-60.17M | $-37.81M | $-44.46M | $-80.69M | $-75.70M | $86.57M | $-71.16M | $-57.17M | $-38.71M | $-39.88M | $202.77M |
| Low Forecast | $-24.54M | $-27.00M | $45.56M | $-19.63M | $-36.81M | $-39.27M | $-36.00M | $-51.28M | $-42.25M | $-91.09M | $-106.38M | $-105.06M | $-150.06M | $-82.81M | $-208.24M | $-99.28M | $-176.16M | $-75.28M | $-95.35M | $-90.25M | $-56.72M | $-66.69M | $-121.04M | $-113.55M | $57.71M | $-106.74M | $-85.75M | $-58.07M | $-59.82M | $135.18M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.51% | 0.43% | 1.29% | 0.43% | 0.83% | - | 1.12% | 0.99% | 0.92% | 0.92% | 1.64% | 1.04% | 0.90% | 1.73% | 0.88% | 0.87% | 1.41% | 1.09% | 0.52% |
Esperion Therapeutics's average Quarter net income forecast for Sep 20 is $-94.63M, with a range of $-113.55M to $-75.70M. ESPR's average Quarter net income forecast represents a -175.94% decrease compared to the company's last Quarter net income of $124.61M (Jun 20).
Esperion Therapeutics SG&A Forecast
| Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $33.24M | $33.96M | $29.90M | $24.14M | $24.95M | - | $30.38M | $38.34M | $39.27M | $46.32M | $61.06M | $61.55M | $48.83M | $47.68M | $41.55M | $21.71M | $18.47M | $13.49M | $12.18M |
| Avg Forecast | $119.47M | $111.73M | $243.52M | $129.00M | $103.86M | $92.81M | $78.18M | $67.15M | $60.30M | $40.65M | $36.37M | $37.57M | $31.29M | $27.91M | $26.16M | $24.99M | $23.64M | $19.56M | $18.38M | $15.10M | $53.56M | $25.31M | $15.90M | $5.09M | $27.60M | $598.46K | $1.13M | $1.14M | $12.40M | $23.56M |
| High Forecast | $147.04M | $137.51M | $299.71M | $158.76M | $127.82M | $114.23M | $96.22M | $79.79M | $74.22M | $48.78M | $41.41M | $46.23M | $38.51M | $34.35M | $32.20M | $30.76M | $23.64M | $22.36M | $21.01M | $17.26M | $61.22M | $28.93M | $18.17M | $5.81M | $33.13M | $684.07K | $1.29M | $1.31M | $14.88M | $28.27M |
| Low Forecast | $96.88M | $90.60M | $197.47M | $104.60M | $84.22M | $75.26M | $63.40M | $59.18M | $48.90M | $32.52M | $28.05M | $30.46M | $25.37M | $22.63M | $21.22M | $20.26M | $23.64M | $17.86M | $16.78M | $13.78M | $48.89M | $23.10M | $14.51M | $4.64M | $22.08M | $546.28K | $1.03M | $1.04M | $9.92M | $18.85M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.88% | 1.09% | 1.07% | 0.92% | 1.00% | - | 1.55% | 2.09% | 2.60% | 0.86% | 2.41% | 3.87% | 9.60% | 1.73% | 69.43% | 19.18% | 16.16% | 1.09% | 0.52% |
Esperion Therapeutics's average Quarter SG&A projection for Dec 23 is $36.37M, based on 6 Wall Street analysts, with a range of $28.05M to $41.41M. The forecast indicates a 9.42% rise compared to ESPR last annual SG&A of $33.24M (Sep 23).
Esperion Therapeutics EPS Forecast
| Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-0.37 | $-0.00 | $-1.14 | $-0.93 | $-1.01 | - | $-1.16 | $-2.13 | $-2.62 | $-1.67 | $-3.50 | $-3.89 | $-3.07 | $4.50 | $-2.84 | $-2.26 | $-2.52 | $-2.01 | $3.26 |
| Avg Forecast | $-0.10 | $-0.11 | $0.32 | $-0.08 | $-0.15 | $-0.16 | $-0.15 | $-0.17 | $-0.17 | $0.05 | $-0.48 | $-0.43 | $-0.61 | $-0.65 | $-0.85 | $-0.93 | $-0.93 | $-1.04 | $-2.27 | $-2.80 | $-1.84 | $-2.52 | $-3.76 | $-3.52 | $1.65 | $-3.30 | $-2.64 | $-1.95 | $-1.12 | $0.64 |
| High Forecast | $-0.08 | $-0.08 | $0.42 | $-0.06 | $-0.11 | $-0.12 | $-0.11 | $-0.07 | $-0.13 | $0.06 | $-0.36 | $-0.32 | $-0.46 | $-0.49 | $-0.64 | $-0.70 | $-0.93 | $-0.92 | $-2.01 | $-2.49 | $-1.63 | $-2.23 | $-3.33 | $-3.12 | $1.95 | $-2.92 | $-2.34 | $-1.73 | $-1.00 | $0.75 |
| Low Forecast | $-0.13 | $-0.14 | $0.24 | $-0.10 | $-0.20 | $-0.21 | $-0.19 | $-0.27 | $-0.22 | $0.04 | $-0.56 | $-0.56 | $-0.79 | $-0.85 | $-1.10 | $-1.20 | $-0.93 | $-1.23 | $-2.69 | $-3.33 | $-2.19 | $-2.98 | $-4.46 | $-4.18 | $1.46 | $-3.91 | $-3.13 | $-2.31 | $-1.33 | $0.56 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.86% | 0.00% | 1.75% | 1.10% | 1.09% | - | 1.12% | 0.94% | 0.93% | 0.91% | 1.39% | 1.03% | 0.87% | 2.73% | 0.86% | 0.86% | 1.29% | 1.79% | 5.13% |
According to 4 Wall Street analysts, Esperion Therapeutics's projected average Quarter EPS for Sep 20 is $-3.52, with a low estimate of $-4.18 and a high estimate of $-3.12. This represents a -178.28% decrease compared to ESPR previous annual EPS of $4.50 (Jun 20).
Esperion Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ESPR | Esperion Therapeutics | $1.78 | $16.00 | 798.88% | Buy |
| PCRX | Pacira BioSciences | $14.35 | $43.00 | 199.65% | Hold |
| IRWD | Ironwood Pharmaceuticals | $4.48 | $11.67 | 160.49% | Buy |
| RMTI | Rockwell Medical | $3.94 | $9.00 | 128.43% | Buy |
| ELAN | Elanco Animal Health | $14.29 | $25.83 | 80.76% | Buy |
| LFCR | Lifecore Biomedical | $5.08 | $8.00 | 57.48% | Buy |
| ALKS | Alkermes | $27.74 | $35.50 | 27.97% | Buy |
| ITCI | Intra-Cellular Therapies | $75.11 | $94.00 | 25.15% | Buy |
| CTLT | Catalent | $60.35 | $74.30 | 23.12% | Hold |
| NBIX | Neurocrine Biosciences | $122.31 | $146.60 | 19.86% | Buy |
| ANIP | ANI Pharmaceuticals | $60.06 | $67.33 | 12.10% | Buy |
| PBH | Prestige Consumer Healthcare | $73.55 | $82.00 | 11.49% | Buy |
| COLL | Collegium Pharmaceutical | $37.38 | $41.50 | 11.02% | Buy |
| AVDL | Avadel Pharmaceuticals | $13.83 | $14.75 | 6.65% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| PAHC | Phibro Animal Health | $22.36 | $18.67 | -16.50% | Buy |
| AGRX | Agile Therapeutics | $1.51 | $1.00 | -33.77% | Buy |
ESPR Forecast FAQ
Is Esperion Therapeutics a good buy?
Yes, according to 8 Wall Street analysts, Esperion Therapeutics (ESPR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 75.00% of ESPR's total ratings.
What is ESPR's price target?
Esperion Therapeutics (ESPR) average price target is $16 with a range of $12 to $20, implying a 798.88% from its last price of $1.78. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Esperion Therapeutics stock go up soon?
According to Wall Street analysts' prediction for ESPR stock, the company can go up by 798.88% (from the last price of $1.78 to the average price target of $16), up by 1023.60% based on the highest stock price target, and up by 574.16% based on the lowest stock price target.
Can Esperion Therapeutics stock reach $3?
ESPR's average twelve months analyst stock price target of $16 supports the claim that Esperion Therapeutics can reach $3 in the near future.
What are Esperion Therapeutics's analysts' financial forecasts?
Esperion Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $245.89M (high $300.39M, low $203.12M), average EBITDA is $-191M (high $-157M, low $-231M), average net income is $-169M (high $-120M, low $-221M), average SG&A $246.28M (high $299.01M, low $203.99M), and average EPS is $-0.443 (high $-0.251, low $-0.649). ESPR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $448.3M (high $551.75M, low $363.53M), average EBITDA is $-370M (high $-300M, low $-456M), average net income is $-13.216M (high $23.01M, low $-50.155M), average SG&A $569.18M (high $700.52M, low $461.55M), and average EPS is $-0.07 (high $0.122, low $-0.266).
Did the ESPR's actual financial results beat the analysts' financial forecasts?
Based on Esperion Therapeutics's last annual report (Dec 2023), the company's revenue was $116.33M, beating the average analysts forecast of $104.86M by 10.95%. Apple's EBITDA was $-156M, beating the average prediction of $-120M by 29.43%. The company's net income was $-209M, missing the average estimation of $-356M by -41.25%. Apple's SG&A was $142.52M, beating the average forecast of $133.13M by 7.05%. Lastly, the company's EPS was $-0.002, missing the average prediction of $-2.173 by -99.91%. In terms of the last quarterly report (Sep 2023), Esperion Therapeutics's revenue was $33.97M, beating the average analysts' forecast of $29.59M by 14.81%. The company's EBITDA was $-27.533M, beating the average prediction of $-24.447M by 12.62%. Esperion Therapeutics's net income was $-41.25M, missing the average estimation of $-80.815M by -48.96%. The company's SG&A was $33.24M, missing the average forecast of $37.57M by -11.51%. Lastly, the company's EPS was $-0.37, missing the average prediction of $-0.428 by -13.56%